These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11281956)

  • 41. MMPI as a measure of subthreshold and residual psychopathology among the offspring of lithium responsive and non-responsive bipolar parents.
    Demidenko N; Grof P; Alda M; Deshauer D; Duffy A
    Bipolar Disord; 2004 Aug; 6(4):323-8. PubMed ID: 15225151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor.
    García-Martín E; Martínez C; Alonso-Navarro H; Benito-León J; Puertas I; Rubio L; López-Alburquerque T; Agúndez JA; Jiménez-Jiménez FJ
    Mov Disord; 2009 Oct; 24(13):1910-5. PubMed ID: 19645064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between Tourette syndrome and the dopamine D3 receptor gene rs6280.
    He F; Zheng Y; Huang HH; Cheng YH; Wang CY
    Chin Med J (Engl); 2015 Mar; 128(5):654-8. PubMed ID: 25698199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. No association between genetic markers in BDNF gene and lithium prophylaxis in a Greek sample.
    Drago A; Serretti A; Smith R; Huezo-Diaz P; Malitas P; Albani D; Ronchi DD; Pae CU; Aitchison KJ
    Int J Psychiatry Clin Pract; 2010 Jun; 14(2):154-7. PubMed ID: 24922477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD; Shults J
    J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DRD3 variation associates with early-onset heroin dependence, but not specific personality traits.
    Kuo SC; Yeh YW; Chen CY; Huang CC; Chang HA; Yen CH; Ho PS; Liang CS; Chou HW; Lu RB; Huang SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jun; 51():1-8. PubMed ID: 24398431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenetics of lithium response in bipolar disorder.
    Alda M
    J Psychiatry Neurosci; 1999 Mar; 24(2):154-8. PubMed ID: 10212559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lack of association between polymorphisms of dopamine receptors, type D2, and bipolar affective illness in a Polish population.
    Leszczyńska-Rodziewicz A; Hauser J; Dmitrzak-Weglarz M; Skibińka M; Czerski P; Zakrzewska A; Kosmowska M; Rybakowski JK
    Med Sci Monit; 2005 Jun; 11(6):CR289-295. PubMed ID: 15917720
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness.
    Manji HK; Moore GJ; Chen G
    J Clin Psychiatry; 2000; 61 Suppl 9():82-96. PubMed ID: 10826666
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association studies of the BDNF and the NTRK2 gene polymorphisms with prophylactic lithium response in bipolar patients.
    Dmitrzak-Weglarz M; Rybakowski JK; Suwalska A; Skibinska M; Leszczynska-Rodziewicz A; Szczepankiewicz A; Hauser J
    Pharmacogenomics; 2008 Nov; 9(11):1595-603. PubMed ID: 19018715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder.
    Maj M; Arena F; Lovero N; Pirozzi R; Kemali D
    Pharmacopsychiatry; 1985 Sep; 18(5):309-13. PubMed ID: 3931108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene and response to lithium prophylaxis in bipolar patients.
    Rybakowski JK; Skibinska M; Suwalska A; Leszczynska-Rodziewicz A; Kaczmarek L; Hauser J
    Hum Psychopharmacol; 2011 Mar; 26(2):168-71. PubMed ID: 21437990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.
    Pisanu C; Heilbronner U; Squassina A
    Mol Diagn Ther; 2018 Aug; 22(4):409-420. PubMed ID: 29790107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular actions and clinical pharmacogenetics of lithium therapy.
    Can A; Schulze TG; Gould TD
    Pharmacol Biochem Behav; 2014 Aug; 123():3-16. PubMed ID: 24534415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.
    Rybakowski JK
    CNS Drugs; 2013 Mar; 27(3):165-73. PubMed ID: 23378337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.
    Squassina A; Manchia M; Del Zompo M
    Hum Genomics Proteomics; 2010 Aug; 2010():159761. PubMed ID: 20981231
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The promise and reality of pharmacogenetics in psychiatry.
    Zandi PP; Judy JT
    Psychiatr Clin North Am; 2010 Mar; 33(1):181-224. PubMed ID: 20159346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.
    Mamdani F; Jaitovich Groisman I; Alda M; Turecki G
    Curr Psychiatry Rep; 2003 Dec; 5(6):484-92. PubMed ID: 14609504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenetics of bipolar disorder.
    Mansour HA; Alda M; Nimgaonkar VL
    Curr Psychiatry Rep; 2002 Apr; 4(2):117-23. PubMed ID: 11914172
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders.
    Serretti A; Lilli R; Lorenzi C; Franchini L; Smeraldi E
    Int J Neuropsychopharmacol; 1998 Dec; 1(2):125-129. PubMed ID: 11281956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.